Review: Small-cell lung cancer: Current perspectives

D. H. Johnson, F. A. Greco

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In summary, combination chemotherapy remains the mainstay of SCLC treatment. Patients with limited-stage disease should be treated aggressively. Under appropriate circumstances, using currently available treatment programs, approximately 2-25% of these patients will survive, free of disease, for 2-3 years. Thoracic irradiation and surgery add to our ability to control intrathoracic disease but as yet have had only minimal impact on survival. Nevertheless, investigation continues as to the exact role these treatment modalities will play in the overall management of SCLC. Extensive-stage patients are less curable and definitely should be considered for entrance into prospective clinical trials. However, even patients with widespread disease can be afforded a measure of palliation with currently available therapy. It is ironic that SCLC is almost completely preventable. An aggressive antismoking attitude is needed among primary-care physicians to help stem the increased incidence of this and other lung neoplasms. Although considerable effort has gone into understanding the biology and treatment of this neoplasm, more lives could be saved if smoking were actively discouraged. Until society comes to grips with this simple fact, our efforts to manage SCLC better must continue.

Original languageEnglish (US)
Pages (from-to)377-389
Number of pages13
JournalAmerican Journal of the Medical Sciences
Volume293
Issue number6
StatePublished - 1987

Fingerprint

Small Cell Lung Carcinoma
Therapeutics
Personal Autonomy
Aptitude
Primary Care Physicians
Combination Drug Therapy
Thoracic Surgery
Lung Neoplasms
Smoking
Clinical Trials
Survival
Incidence
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Review : Small-cell lung cancer: Current perspectives. / Johnson, D. H.; Greco, F. A.

In: American Journal of the Medical Sciences, Vol. 293, No. 6, 1987, p. 377-389.

Research output: Contribution to journalArticle

@article{478c38338c254eebad9ff94c634af2cb,
title = "Review: Small-cell lung cancer: Current perspectives",
abstract = "In summary, combination chemotherapy remains the mainstay of SCLC treatment. Patients with limited-stage disease should be treated aggressively. Under appropriate circumstances, using currently available treatment programs, approximately 2-25{\%} of these patients will survive, free of disease, for 2-3 years. Thoracic irradiation and surgery add to our ability to control intrathoracic disease but as yet have had only minimal impact on survival. Nevertheless, investigation continues as to the exact role these treatment modalities will play in the overall management of SCLC. Extensive-stage patients are less curable and definitely should be considered for entrance into prospective clinical trials. However, even patients with widespread disease can be afforded a measure of palliation with currently available therapy. It is ironic that SCLC is almost completely preventable. An aggressive antismoking attitude is needed among primary-care physicians to help stem the increased incidence of this and other lung neoplasms. Although considerable effort has gone into understanding the biology and treatment of this neoplasm, more lives could be saved if smoking were actively discouraged. Until society comes to grips with this simple fact, our efforts to manage SCLC better must continue.",
author = "Johnson, {D. H.} and Greco, {F. A.}",
year = "1987",
language = "English (US)",
volume = "293",
pages = "377--389",
journal = "The American journal of the medical sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Review

T2 - Small-cell lung cancer: Current perspectives

AU - Johnson, D. H.

AU - Greco, F. A.

PY - 1987

Y1 - 1987

N2 - In summary, combination chemotherapy remains the mainstay of SCLC treatment. Patients with limited-stage disease should be treated aggressively. Under appropriate circumstances, using currently available treatment programs, approximately 2-25% of these patients will survive, free of disease, for 2-3 years. Thoracic irradiation and surgery add to our ability to control intrathoracic disease but as yet have had only minimal impact on survival. Nevertheless, investigation continues as to the exact role these treatment modalities will play in the overall management of SCLC. Extensive-stage patients are less curable and definitely should be considered for entrance into prospective clinical trials. However, even patients with widespread disease can be afforded a measure of palliation with currently available therapy. It is ironic that SCLC is almost completely preventable. An aggressive antismoking attitude is needed among primary-care physicians to help stem the increased incidence of this and other lung neoplasms. Although considerable effort has gone into understanding the biology and treatment of this neoplasm, more lives could be saved if smoking were actively discouraged. Until society comes to grips with this simple fact, our efforts to manage SCLC better must continue.

AB - In summary, combination chemotherapy remains the mainstay of SCLC treatment. Patients with limited-stage disease should be treated aggressively. Under appropriate circumstances, using currently available treatment programs, approximately 2-25% of these patients will survive, free of disease, for 2-3 years. Thoracic irradiation and surgery add to our ability to control intrathoracic disease but as yet have had only minimal impact on survival. Nevertheless, investigation continues as to the exact role these treatment modalities will play in the overall management of SCLC. Extensive-stage patients are less curable and definitely should be considered for entrance into prospective clinical trials. However, even patients with widespread disease can be afforded a measure of palliation with currently available therapy. It is ironic that SCLC is almost completely preventable. An aggressive antismoking attitude is needed among primary-care physicians to help stem the increased incidence of this and other lung neoplasms. Although considerable effort has gone into understanding the biology and treatment of this neoplasm, more lives could be saved if smoking were actively discouraged. Until society comes to grips with this simple fact, our efforts to manage SCLC better must continue.

UR - http://www.scopus.com/inward/record.url?scp=0023235713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023235713&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023235713

VL - 293

SP - 377

EP - 389

JO - The American journal of the medical sciences

JF - The American journal of the medical sciences

SN - 0002-9629

IS - 6

ER -